scholarly journals Clinicopathological and prognostic significance of osteopontin expression in patients with prostate cancer: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Anze Yu ◽  
Kai Guo ◽  
Qilin Qin ◽  
Changsheng Xing ◽  
Xiongbing Zu
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Cochrane Library ◽  
China National Knowledge Infrastructure ◽  
Normal Prostate ◽  
Knowledge Infrastructure ◽  
Online Databases ◽  
Cancer Tissues

Background: Evaluation of the feasibility for osteopontin (OPN) to serve as a biomarker in the prognosis and clinical-pathological features of prostate cancer patients. Methods: The original publications related to osteopontin and prostate cancer were comprehensively searched in the online databases, including PubMed, Embase, Cochrane Library, Web of Science, Medline, Wanfang and China National Knowledge Infrastructure up to August 2019. Results were analyzed by Revman 5.3 and Stata 12.0. Results: A total of 21 studies were included in the analysis and the result showed that the positive OPN expression group had a lower overall survival than the negative expression group (univariate: HR=2.32, 95%CI [1.74, 3.10], multivariate: HR=2.41, 95%CI [1.63, 3.57]) and a lower biochemical relapse-free survival than the negative group (univariate: HR=1.42, 95%CI [0.92, 2.17], multivariate: HR=1.61, 95%CI [1.39, 1.87]). In addition, there was a higher expression level of OPN in prostate cancer tissues than in normal prostate tissues (OR=46.55, 95%CI [12.85, 168.59], P<0.00001) and benign prostatic hyperplasia tissues (OR=11.07, 95%CI [3.43, 35.75], P<0.0001). Moreover, OPN positive expression was also related to high Gleason score (OR=2.64, 95%CI [1.49, 4.70], P=0.0009), high TNM stage (OR=3.15, 95%CI [1.60, 6.20, P=0.0009), high Whitmore-Jewett stage (OR=2.53, 95%CI [1.06, 6.03], P=0.04), high lymph node (OR=3.69, 95%CI [1.88, 7.23], P=0.0001), and distant metastasis (OR=8.10, 95%CI [2.94, 22.35], P=0.01). There was no difference observed in the differentiation of prostate cancer (OR=1.79, 95%CI [0.39, 8.33], P=0.46). Conclusion: Osteopontin could be recognized as a promising diagnostic and prognostic biomarker for prostate cancer patients.

scholarly journals Osteopontin as a Novel Biomarker for the Prognosis and Clinical Pathology of Prostate Cancer: A Systematic Review and Meta-Analysis

2020 ◽  
Author(s):  
Anze Yu ◽  
Kai Xie ◽  
Changsheng Xing ◽  
Qilin Qin ◽  
Longfei Liu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Clinical Pathology ◽  
Cochrane Library ◽  
China National Knowledge Infrastructure ◽  
Normal Prostate ◽  
Knowledge Infrastructure ◽  
Online Databases ◽  
Cancer Tissues

Abstract Background: Evaluation of the feasibility for osteopontin (OPN) to serve as a biomarker in the prognosis and clinical pathological features of prostate cancer patients.Methods: The original publications related to osteopontin and prostate cancer were comprehensively searched in the online databases, including PubMed, Embase, Cochrane Library, Web of Science, Medline, Wanfang database and China National Knowledge Infrastructure up to August 2019. Results were analyzed by software Revman 5.3 and Stata 12.0. Results: A total of 21 studies were included in the analysis and the result showed that the positive OPN expression group had a lower overall survival than the negative expression group (univariate: HR=2.32, 95%CI [1.74, 3.10], multivariate: HR=2.41, 95%CI [1.63, 3.57]) and a lower biochemical relapse-free survival than the negative group (univariate: HR=1.42, 95%CI [0.92, 2.17], multivariate: HR=1.61, 95%CI [1.39, 1.87]). In addition, there was a higher expression level of OPN in prostate cancer tissues than in normal prostate tissues (OR=46.55, 95%CI [12.85, 168.59], p<0.00001) and benign prostatic hyperplasia tissues (OR=11.07, 95%CI [3.43, 35.75], p<0.0001). Moreover, OPN positive expression was also related to high Gleason score (OR=2.64, 95%CI [1.49, 4.70], p=0.0009), high TNM stage (OR=3.15, 95%CI [1.60, 6.20, p=0.0009), high Whitmore-Jewett stage (OR=2.53, 95%CI [1.06, 6.03], p=0.04), high lymph node (OR=3.69, 95%CI [1.88, 7.23], p=0.0001), and distant metastasis (OR=8.10, 95%CI [2.94, 22.35], p=0.01). There was no difference observed in the differentiation of prostate cancer (OR=1.79, 95%CI [0.39, 8.33], p=0.46).Conclusion: Osteopontin could be recognized as a promising novel diagnostic and prognostic biomarker for prostate cancer patients.

scholarly journals Osteopontin as a novel biomarker for the prognosis and clinical pathology of prostate cancer: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Anze Yu ◽  
Kai Xie ◽  
Changsheng Xing ◽  
Qilin Qin ◽  
Longfei Liu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Clinical Pathology ◽  
Cochrane Library ◽  
China National Knowledge Infrastructure ◽  
Normal Prostate ◽  
Knowledge Infrastructure ◽  
Online Databases ◽  
Cancer Tissues

Abstract Background Evaluation of the feasibility for osteopontin (OPN) to serve as a biomarker in the prognosis and clinical pathological features of prostate cancer patients.Methods The original publications related to osteopontin and prostate cancer were comprehensively searched in the online databases, including PubMed, Embase, Cochrane Library, Web of Science, Medline, Wanfang database and China National Knowledge Infrastructure up to August 2019. Results were analyzed by software Revman 5.3 and Stata 12.0.Results A total of 21 studies were included in the analysis and the result showed that the positive OPN expression group had a lower overall survival than the negative expression group (univariate: HR = 2.32, 95%CI [1.74, 3.10], multivariate: HR = 2.41, 95%CI [1.63, 3.57]) and a lower biochemical relapse-free survival than the negative group (univariate: HR = 1.42, 95%CI [0.92, 2.17], multivariate: HR = 1.61, 95%CI [1.39, 1.87]). In addition, there was a higher expression level of OPN in prostate cancer tissues than in normal prostate tissues (OR = 46.55, 95%CI [12.85, 168.59], p < 0.00001) and benign prostatic hyperplasia tissues (OR = 11.07, 95%CI [3.43, 35.75], p < 0.0001). Moreover, OPN positive expression was also related to high Gleason score (OR = 2.64, 95%CI [1.49, 4.70], p = 0.0009), high TNM stage (OR = 3.15, 95%CI [1.60, 6.20, p = 0.0009), high Whitmore-Jewett stage (OR = 2.53, 95%CI [1.06, 6.03], p = 0.04), high lymph node (OR = 3.69, 95%CI [1.88, 7.23], p = 0.0001), and distant metastasis (OR = 8.10, 95%CI [2.94, 22.35], p = 0.01). There was no difference observed in the differentiation of prostate cancer (OR = 1.79, 95%CI [0.39, 8.33], p = 0.46).Conclusion Osteopontin could be recognized as a promising novel diagnostic and prognostic biomarker for prostate cancer patients.

scholarly journals Abnormal COX2 Protein Expression May Be Correlated with Poor Prognosis in Oral Cancer: A Meta-Analysis

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Zhi-Ming Wang ◽  
Jie Liu ◽  
Hong-Bo Liu ◽  
Ming Ye ◽  
Yu-Fei Zhang ◽  
...  
Keyword(s):  
Oral Cancer ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Final Analysis ◽  
Cochrane Library ◽  
Oral Cancer Patients ◽  
The Cochrane Library ◽  
Cancer Tissues ◽  
Cox2 Expression

Background.The prognostic significance of COX2 for survival of patients with oral cancer remains controversial. Thus, the meta-analysis was performed in order to identify COX2 expression impact on prognosis of oral cancer.Method.Relevant literatures were searched using the following electronic databases without any language restrictions: Web of Science, the Cochrane Library Database, PubMed, EMBASE, CINAHL, and CBM. Version 12.0 STATA software (Stata Corporation, College Station, Texas, USA) was used for the current meta-analysis. Odds ratios (ORs) and hazard ratios (HRs) with their corresponding 95% confidence interval (95% CI) were also calculated to clarify the correlation between COX2 expression and prognosis of oral cancer.Results.Final analysis of 979 oral cancer patients from 12 clinical cohort studies was performed. The meta-analysis results show that COX2 expression in cancer tissues was significantly higher than those in normal and benign tissues (allP< 0.05). Combined HR of COX2 suggests that positive COX2 expression has a shorter overall survival (OS) than those of negative COX2 expression (P< 0.05).Conclusion.The meta-analysis study shows that elevated COX2 expression may be associated with the pathogenesis of oral cancer and with a worse prognosis in oral cancer patients.

scholarly journals Associations of CYP1 polymorphisms with risk of prostate cancer: an updated meta-analysis

2019 ◽  
Vol 39 (3) ◽  
Author(s):  
Wei Zhu ◽  
Hailang Liu ◽  
Xinguang Wang ◽  
Jinjin Lu ◽  
Huiping Zhang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Meta Analysis ◽  
Random Effect ◽  
Asian Population ◽  
Caucasian Population ◽  
Cochrane Library ◽  
China National Knowledge Infrastructure ◽  
Knowledge Infrastructure ◽  
Cyp1a1 Gene ◽  
Major Allele

Abstract Background. The results of previous studies on the association between polymorphisms of CYP1A1 and CYP1B1 and prostate cancer (PCa) susceptibility are inconsistent. The aim of the present study was to conduct a meta-analysis in order to better estimate this association. Methods. A systematic search was carried out on PubMed, Embase, Cochrane Library, and China National Knowledge Infrastructure (CNKI) databases for relevant articles published up to 15 August 2018. Pooled odds ratios (ORs) and 95% confidence intervals were obtained using fixed-effect or random-effect models. Results. A significant association was found between the CYP1A1 rs1048943 polymorphism and PCa in the overall population (B [the minor allele] vs. A [the major allele]: OR = 1.20, 95% confidence interval (CI) = 1.04–1.39, P=0.014; AB vs. AA: OR = 1.24, 95% CI = 1.02–1.51, P=0.029; BB + AB vs. AA: OR = 1.25, 95% CI = 1.04–1.50, P=0.018) and Asian population (B vs. A: OR = 1.32, 95% CI = 1.11–1.56, P=0.001; BB vs. AA: OR = 1.81, 95% CI = 1.20–2.72, P=0.005; AB vs. AA: OR = 1.30, 95% CI = 1.03–1.64, P=0.029; BB + AB vs. AA: OR = 1.38, 95% CI = 1.11–1.73, P=0.004; BB vs. AA + AB: OR = 1.58, 95% CI = 1.08–2.01, P=0.019), but not in the Caucasian population. Moreover, we found that the rs4646903 polymorphism was associated with a significant increase in the risk of PCa in the Asian population (AB vs. AA: OR = 1.43, 95% CI = 1.13–1.80, P=0.003) and Caucasian population (BB vs. AA: OR = 2.12, 95% CI = 1.29–3.49, P=0.003). Conclusion. This meta-analysis revealed a clear association between rs1048943 and rs4646903 polymorphisms of the CYP1A1 gene but not between CYP1B1 rs10012, rs162549, rs1800440, and rs2551188 polymorphisms and the risk of PCa.

scholarly journals Effect of somatometric parameters on the prevalence and severity of varicocele: a systematic review and meta-analysis

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Runqing Li ◽  
Junjie Liu ◽  
Yushan Li ◽  
Quanxian Wang
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Cochrane Library ◽  
China National Knowledge Infrastructure ◽  
Random Effects Models ◽  
Knowledge Infrastructure ◽  
Regression Test ◽  
Mean Differences ◽  
Q Statistic ◽  
The Relationship

Abstract Background Published studies have shown contradictory results regarding the relationship between somatometric parameters and varicoceles. We performed a systematic review and meta-analysis to investigate the possible effects of age, height, weight, and body mass index (BMI) on the presence and severity of varicoceles. Methods Databases including EMBASE, MEDLINE, PubMed, Cochrane Library, China National Knowledge Infrastructure (CNKI), Web of Science, and Google Scholar were systematically searched to identify relevant articles published up to March 2020. Two researchers independently identified eligible articles and extracted data. Cochran’s Q statistic and I2 statistics were used to assess heterogeneity. Meta-analysis was performed using StataSE 12.0 software (StataCorp LP, USA). Random-effects models were used to obtain the weighted mean differences (WMDs) and 95% confidence intervals (CIs). Publication bias was assessed using Begg’s funnel plot and Egger’s regression test. Results The search strategy produced 272 articles, of which 18 articles were eligible according to the inclusion/exclusion criteria. A total of 56,325 patients with varicocele and 1,334,694 patients without varicocele were included in the meta-analysis to evaluate the effect of somatometric parameters on the presence and severity of varicocele. The overall results demonstrated that the presence of varicoceles was significantly associated with height (WMD = 1.41, 95% CI = 1.07 to 1.74, P < 0.001) and inversely correlated with BMI (WMD = − 1.35, 95% CI = -1.67 to − 1.03, P < 0.001) but not with age (WMD = -0.93, 95% CI = -2.19 to 0.33, P = 0.149) or weight (WMD = 0.24, 95% CI = -2.24 to 2.72, P = 0.850). The severity of varicocele was inversely correlated with increased BMI but not with age. Conclusion The presence of varicoceles was significantly associated with height and inversely correlated with BMI.

scholarly journals Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Chuang Jiang ◽  
Gong Cheng ◽  
Mingheng Liao ◽  
Jiwei Huang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Transcatheter Arterial Chemoembolization ◽  
Meta Analysis ◽  
Combined Treatment ◽  
Similar Rate ◽  
Cochrane Library ◽  
China National Knowledge Infrastructure ◽  
Knowledge Infrastructure ◽  
Arterial Chemoembolization

Abstract Background There is still some debate as to whether transcatheter arterial chemoembolization (TACE) plus radiofrequency ablation (RFA) is better than TACE or RFA alone. This meta-analysis aimed to compare the efficacy and safety of TACE plus RFA for hepatocellular carcinoma (HCC) with RFA or TACE alone. Methods We searched PubMed, MEDLINE, Embase, Cochrane Library, and CNKI (China National Knowledge Infrastructure) for all relevant randomized controlled trials and retrospective studies reporting overall survival (OS), recurrence-free survival (RFS), and complications of TACE plus RFA for HCC, compared with RFA or TACE alone. Results Twenty-one studies involving 3413 patients were included. TACE combined with RFA was associated with better OS (hazard ratio [HR]=0.62, 95% confidence intervals [CI] = 0.55–0.71, P < 0.001) and RFS (HR = 0.52, 95% CI = 0.39–0.69, P < 0.001) than TACE alone; compared with RFA alone, TACE plus RFA resulted in longer OS (HR = 0.63, 95% CI = 0.53–0.75, P < 0.001) and RFS (HR = 0.60, 95% CI = 0.51–0.71, P < 0.001). Subgroup analyses by tumor size also showed that combined treatment resulted in better OS and RFS compared with RFA alone in patients with HCC larger than 3 cm. Combined treatment resulted in similar rate of major complications compared with TACE or RFA alone (OR = 1.78, 95% CI = 0.99–3.20, P = 0.05; OR = 1.00, 95% CI = 0.42–2.38, P = 1.00, respectively). Conclusions TACE combined with RFA was more effective for HCC than TACE alone. For patients with a tumor larger than 3 cm, the combined treatment also achieved a better effect than RFA alone.

scholarly journals Association of inflammatory markers with the severity of COVID-19

2020 ◽  
Author(s):  
Furong Zeng ◽  
Ying Guo ◽  
Mingzhu Yin ◽  
Xiang Chen ◽  
Guangtong Deng
Keyword(s):  
Inflammatory Markers ◽  
Fixed Effects ◽  
Weighted Mean Difference ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Global Public Health ◽  
China National Knowledge Infrastructure ◽  
Bias Assessment ◽  
Knowledge Infrastructure ◽  
Severe Group

AbstractBackgroundThe ongoing worldwide epidemic of Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2), has posed a huge threat to global public health. However, with regard to the effects of inflammatory markers on the severity of COVID-19, studies have reported associations that vary in strength and direction.AimsIn the meta-analysis, we aimed to provide an overview of the association of inflammatory markers with severity of COVID-19.MethodsThe following databases were searched: PubMed, Embase, Cochrane Library, Wanfang database and CNKI (China National Knowledge Infrastructure) database until March 20, 2020. Weighted mean difference (WMD) and 95% confidence intervals (CIs) were pooled using random or fixed-effects models.ResultsA total of 16 studies were included in our analysis comprising of 3962 patients with COVID-19. Random-effects results demonstrated that patients with COVID-19 in non-severe group had lower levels for CRP (WMD = -41.78 mg/l, 95% CI = [-52.43, - 31.13], P < 0.001), PCT (WMD = -0.13 ng/ml, 95% CI = [-0.20, -0.05], P < 0.001), IL- 6 (WMD = -21.32 ng/l, 95% CI = [-28.34, -14.31], P < 0.001), ESR (WMD = - 8.40 mm/h, 95% CI = [-14.32, -2.48], P = 0.005), SAA (WMD = -43.35 μg/ml, 95% CI = [-80.85, -5.85], P = 0.020) and serum ferritin (WMD = -398.80 mg/l, 95% CI = [- 625.89, -171.71], P < 0.001), compared with those in severe group. Moreover, survivors had lower level for IL-6 than non-survivors with COVID-19 (WMD = -4.80 ng/ml, 95% CI = [-5.87, -3.73], P < 0.001). These results were consistent through sensitivity analysis and publication bias assessment.ConclusionsThe meta-analysis highlights the association of inflammatory markers with the severity of COVID-19. Measurement of inflammatory markers might help clinicians to monitor and evaluate the severity and prognosis of COVID-19.

scholarly journals Efficacy and Safety of Modified Yunu-Jian in Patients with Periodontitis: A Meta-Analysis

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Yuanyuan Yue ◽  
Meng Gao ◽  
Yanru Deng ◽  
Jiemin Shao ◽  
Yingguang Sun
Keyword(s):  
Western Medicine ◽  
Combined Therapy ◽  
Meta Analysis ◽  
Effective Rate ◽  
Cochrane Library ◽  
Efficacy And Safety ◽  
China National Knowledge Infrastructure ◽  
Knowledge Infrastructure ◽  
Oral Inflammation

Background. Modified Yunu-Jian (mYJ), a Chinese medicine (CM) formula, is thought to clear heat and nourish yin. Clinically, it is often used to treat oral inflammation. However, its efficacy remains controversial. Methods. The study aims to evaluate the efficacy and safety of mYJ for treating patients with periodontitis. We searched electronic databases (PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure, Wanfang database, VIP database, and CBM) from inception to December 2020. Only randomized controlled trials investigating modified Yunu-Jian, with or without other medications, against controlled intervention in the treatment of patients diagnosed with periodontitis were included. Both Review Manager 5.3 and Stata 15.0 software were used to analyze the data. The Cochrane Collaborations risk of bias tool was used to assess the quality of the methods. Results. Thirteen clinical trials, involving 1179 participants, were included in our investigation. The results showed that the combination of mYJ with western medicine improved the total effective rate compared with western medicine alone (RR = 1.17, 95% CI (1.12, 1.23), P  < 0.00001). The sensitivity analysis and Harbord’s test ( P  = 0.255) both showed that the results were statistically robust. Moreover, the periodontal indexes (GI, SBI, PLI, and PD; P  < 0.00001) of patients with periodontitis were also significantly improved after receiving the combined therapy. No serious adverse reactions were observed in the experimental groups. Conclusions. Evidence from the meta-analysis suggested that mYJ appeared to be effective and relatively safe for treating periodontitis. Because of the low quality of the methods used in the included RCTs, further studies with larger sample sizes and well-designed models are required to confirm our findings.

scholarly journals Large Dosage of Chishao in Formulae for Cholestatic Hepatitis: A Systematic Review and Meta-Analysis

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Xiao Ma ◽  
Ji Wang ◽  
Xuan He ◽  
Yanling Zhao ◽  
Jiabo Wang ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Cholestatic Hepatitis ◽  
Cochrane Library ◽  
Efficacy Rate ◽  
China National Knowledge Infrastructure ◽  
Randomized Controlled ◽  
Knowledge Infrastructure ◽  
Novel Treatment ◽  
Large Dosage ◽  
Biochemical Indices

Objective. To evaluate the efficacy and safety of large dosage of Chishao in formulae for treatment of cholestatic hepatitis.Methods. The major databases (PubMed, Embase, Cochrane Library, Chinese Biomedical Database Wanfang, VIP medicine information system, and China National Knowledge Infrastructure) were searched until January 2014. Randomized controlled trials (RCTs) of large dosage of Chishao in formulae that reported on publications in treatment of cholestatic hepatitis with total efficacy rate, together with the biochemical indices including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), and direct bilirubin (DBIL), were extracted by two reviewers. The Cochrane tool was used for the assessment of risk of bias included trials. Data were analyzed with RevMan 5.2.7 software.Results. 11 RCTs involving 1275 subjects with cholestatic hepatitis were included. Compared with essential therapy, large dosage of Chishao in formulae demonstrated more efficiently with down regulation of serum ALT, AST, TBIL, DBIL. Meanwhile, there were no obvious adverse events.Conclusion. As a promising novel treatment approach, widely using large dosage of Chishao in formulae may enhance the curative efficacy for cholestatic hepatitis. Considering being accepted by more and more practitioners, further rigorously designed clinical studies are required.

scholarly journals The Clinicopathological and Prognostic Significance of IDO1 Expression in Human Solid Tumors: Evidence from a Systematic Review and Meta-Analysis

2018 ◽  
Vol 49 (1) ◽  
pp. 134-143 ◽  
Author(s):  
Cheng-Peng Yu ◽  
Shu-Fang Fu ◽  
Xuan Chen ◽  
Jing Ye ◽  
Yuan Ye ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cancer Patients ◽  
Solid Tumors ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
High Expression ◽  
Cochrane Library ◽  
Odds Ratios ◽  
Ido1 Expression ◽  
Human Solid Tumors

Background/Aims: Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-containing enzyme catalyzing the initial and rate-limiting steps in the kynurenine pathway, which converts tryptophan into kynurenine. Upregulation of IDO1 decreases tryptophan levels and increases the accumulation of kynurenine and its metabolites. These metabolites can affect the proliferation of T cells. Increasing evidence has shown that IDO1 is highly expressed in various cancer types and associated with poor prognosis of cancer patients. However, the results were inconsistent. Methods: We searched the Web of Science, PubMed, Embase and Cochrane library databases to identify studies evaluating the prognostic value of IDO1 in cancer patients. Pooled hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated by using fixed-effects/random-effects models. Results: This systematic review and meta-analysis included 2706 patients from 24 articles. The results indicated a shorter overall survival in patients with high expression of IDO1 (hazard ratio [HR] = 2.03, 95% confidence interval [CI]: 1.56-2.63). Furthermore, disease-free survival was worse in patients with high expression of IDO1 (HR = 2.47, 95% CI: 1.46-4.20). Additionally, the pooled odds ratios (ORs) showed that increased IDO1 was significantly associated with tumor differentiation (OR = 1.81, 95% CI: 1.05-3.12), distant metastasis (OR = 1.45, 95% CI: 1.02-2.06), and poor clinical stage (OR = 1.89, 95% CI: 1.13-3.17). However, no significant correlation was observed of increased IDO1 expression with age, sex, lymph node metastasis, and tumor size. Conclusion: High expression of IDO1 is associated with poor clinical outcomes. IDO1 could serve as a biomarker of prognosis and a potential predictive factor of clinicopathology in various cancers. Further studies should be performed to verify the clinical utility of IDO1 in human solid tumors.

Sign in / Sign up

Export Citation Format

Share Document